Despite the importance of this gene product in the pharmacology of depression, recent GWAS studies report no association between candidate polymorphisms at SLC6A4 (or a number of other candidate genes) and major depression (Border et al., 2019). This evidence concerns the gene SLC6A4 and depressive disorder.